HLTF Linked to Prostate Cancer Cell Growth in Laboratory Study

A multi-method prostate cancer study reports that the gene HLTF was highly expressed in prostate cancer cells, while reducing its expression diminished their ability to proliferate. The researchers also found evidence suggesting that HLTF may influence a cell-death process through the ZBP1-PANoptosome complex. The investigators first used differential gene-expression analysis to identify pan-apoptosis-related genes and clustered prostate cancer samples into two molecular groups.

They then developed a prognostic model incorporating four core genes, producing groups designated low PANS and high PANS. According to the study abstract, the model demonstrated robust performance in prognostic prediction. The supplied evidence does not report the patient-cohort size, the model’s performance metrics, details of external validation, or whether the predictions were tested prospectively, so the reported prognostic performance cannot be evaluated in full from the available material.

The model-based analysis also identified a difference between the two groups in estimated immune-microenvironment characteristics. Samples in the low-PANS group had higher TIDE scores than those in the high-PANS group. The authors interpreted this result as suggesting that patients with low-PANS tumors might have a less favorable response to immune checkpoint blockade therapy.

This is a computational association rather than evidence from patients receiving checkpoint inhibitors, and the treatment-response implication therefore remains unverified clinically. HLTF was selected for further investigation after the researchers found that it was highly expressed in PRAD cells, which the study identifies as prostate adenocarcinoma cells. Functional experiments showed that prostate cancer cell proliferation diminished following HLTF knockdown, indicating that HLTF supported cell growth under the conditions tested.

The study further suggested a possible mechanism for this effect: HLTF may regulate pan-apoptosis by modulating ZBP1-PANoptosome assembly. EdU assays, quantitative real-time PCR and Western blotting were used to validate experimental observations, while the findings regarding the complex are presented as evidence of a potential mechanistic link rather than a completed therapeutic mechanism. The researchers also used molecular docking to identify several compounds and drugs associated with HLTF, including the small-molecule compound EGCG.

In laboratory experiments, EGCG interacted with HLTF and reversed the enhanced proliferative capacity induced by HLTF overexpression in prostate cancer cells. This result supports EGCG and other HLTF-binding compounds as candidates for further preclinical evaluation, but the evidence does not show that EGCG treats prostate cancer in people, that it acts through HLTF in clinical settings, or that targeting HLTF would improve patient outcomes. The study is best understood as a combined prognostic, mechanistic and drug-candidate investigation whose clinical relevance requires additional validation.

Subject of Research: HLTF-associated prostate cancer cell proliferation and pan-apoptosis regulation

Article Title: PANoptosis-related HLTF promotes prostate cancer progression and serves as a potential therapeutic target

Article References: Xin, S., Li, R., Zhao, L., Su, J., Li, G., Qin, W., Zhang, Z., Wang, C., Zhu, Y., Feng, L., Sun, X., Jin, L., Zhai, T., Mei, W., & Gao, Z. (2026). PANoptosis-related HLTF promotes prostate cancer progression and serves as a potential therapeutic target. BMC Cancer. https://doi.org/10.1186/s12885-026-16876-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16876-5

Keywords: prostate cancer, HLTF, pan-apoptosis, ZBP1, PANoptosome, EGCG, prognostic modeling, cell proliferation, molecular docking, tumor microenvironment, PANoptosis-related, promotes